Companies Alumis Inc
Alumis (ALMS): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Alumis Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $10,661,219FY2024
- $5,948,289FY2025
CEO total pay was $5,948,289 in fiscal 2025, down from $10,661,219 in fiscal 2024.
FY2025: salary $680,830 · bonus $0 · stock awards $0 · option awards $4,743,220
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Martin Babler | $680,830 | $0 | $0 | $4,743,220 | $524,239 | $0 | $0 | $5,948,289 |
| President, Chief Executive Officer, and Chairman of the Board | ||||||||
| David Goldstein | 526,401 | 0 | 0 | 1,187,353 | 294,785 | 0 | 0 | 2,008,539 |
| Chief Scientific Officer | ||||||||
| Jörn Drappa | 523,755 | 0 | 0 | 1,161,607 | 293,303 | 0 | 0 | 1,978,665 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Martin Babler | $5,948,289 | $10,661,219 | — | ↓ −4,712,930 |
| David Goldstein | 2,008,539 | 3,244,462 | — | ↓ −1,235,923 |
| Jörn Drappa | 1,978,665 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Board considers market compensation for comparable positions, historical compensation levels, individual performance against expectations, and the desire to motivate employees to achieve short- and long-term results in the best interests of stockholders. Equity awards are used as the primary vehicle for long-term incentives to align executive interests with stockholders and create an ownership culture.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| David Goldstein | Option | 892 | 8.84 | — |
| Martin Babler | Option | 2,229 | 8.84 | — |
| Jörn Drappa | Option | 3,342 | 16 | — |
| Jörn Drappa | Option | 4,546 | 8.84 | — |
| David Goldstein | Option | 5,303 | 8.84 | — |
| Jörn Drappa | Option | 8,549 | 8.84 | — |
| Martin Babler | Option | 13,369 | 16 | — |
| David Goldstein | Option | 14,045 | 8.84 | — |
| Jörn Drappa | RSU | 25,450 | — | 248,392 |
| David Goldstein | RSU | 27,000 | — | 263,520 |
| Jörn Drappa | Option | 28,521 | 8.84 | — |
| Jörn Drappa | Option | 30,682 | 8.84 | — |
| David Goldstein | Option | 33,422 | 13.32 | — |
| Jörn Drappa | Option | 38,218 | 8.84 | — |
| Jörn Drappa | Option | 40,107 | 13.32 | — |
| Martin Babler | Option | 49,055 | 8.84 | — |
| David Goldstein | Option | 59,715 | 8.84 | — |
| Martin Babler | Option | 93,182 | 8.84 | — |
| Jörn Drappa | Option | 101,850 | 3.95 | — |
| David Goldstein | Option | 107,950 | 3.95 | — |
| Martin Babler | Option | 135,681 | 8.84 | — |
| Martin Babler | Option | 150,000 | 3.95 | — |
| Martin Babler | Option | 153,742 | 13.32 | — |
| David Goldstein | Option | 180,000 | 5.06 | — |
| Jörn Drappa | Option | 180,000 | 5.06 | — |
| Martin Babler | Option | 186,609 | 8.84 | — |
| Martin Babler | Option | 523,000 | 5.06 | — |
| Martin Babler | Option | 662,000 | 3.95 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Patrick Machado, J.DIndependent · Audit (Chair) · Nominating and Corporate Governance | $65,000 | — | $161,307 | — | — | $226,307 |
| Sapna Srivastava, Ph.DIndependent · Lead Independent Director · Nominating and Corporate Governance | 64,423 | — | 161,307 | — | — | 225,730 |
| Srinivas Akkaraju, M.D., Ph.DIndependent · Audit · Science and Technology | 52,651 | — | 161,307 | — | — | 213,958 |
| Zhengbin (Bing) Yao, Ph.DIndependent · Nominating and Corporate Governance · Science and Technology | 51,360 | — | 161,307 | — | — | 212,667 |
| Lynn Tetrault, J.DIndependent · Compensation | 28,832 | — | 161,307 | — | — | 190,139 |
| James B. Tananbaum, M.DIndependent · Compensation · Science and Technology | 0 | — | 0 | — | — | 0 |
| Martin BablerEmployee director · Board Chair | — | — | — | — | — | 0 |
| Alan B. Colowick, M.D., M.P.HIndependent · Audit · Compensation · Science and Technology | 0 | — | 0 | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $262,266 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $262,266 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Alumis as a peer
Companies that benchmark against ALMS
2 companies name ALMS as a compensation peer
- Jade Biosciences, Inc.JBIOFY2025
- Olema Pharmaceuticals, Inc.OLMAFY2025
Each company listed discloses ALMS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ALMS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Alumis Inc | 2025 | Martin Babler | $680,830 | $0 | $4,743,220 | $524,239 | $5,948,289 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (14 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Martin Babler. DEF 14A, filed 2026-05-18. Section “Summary Compensation Table” · page 28. As printed: 5,948,289. View filing ↗
- Section 01, David Goldstein. DEF 14A, filed 2026-05-18. Section “Summary Compensation Table”. As printed: 2,008,539. View filing ↗
- Section 01, Jörn Drappa. DEF 14A, filed 2026-05-18. Section “Summary Compensation Table”. As printed: 1,978,665. View filing ↗
- Section 08, Patrick Machado, J.D. DEF 14A, filed 2026-05-18. Section “Director Compensation”. As printed: 226,307. View filing ↗
- Section 08, Sapna Srivastava, Ph.D. DEF 14A, filed 2026-05-18. Section “Director Compensation”. As printed: 225,730. View filing ↗
- Section 08, Srinivas Akkaraju, M.D., Ph.D. DEF 14A, filed 2026-05-18. Section “Director Compensation”. As printed: 213,958. View filing ↗
- Section 08, Zhengbin (Bing) Yao, Ph.D. DEF 14A, filed 2026-05-18. Section “Director Compensation”. As printed: 212,667. View filing ↗
- Section 08, Lynn Tetrault, J.D. DEF 14A, filed 2026-05-18. Section “Director Compensation”. As printed: 190,139. View filing ↗
- Section 08, James B. Tananbaum, M.D. DEF 14A, filed 2026-05-18. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Martin Babler. DEF 14A, filed 2026-05-18. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Alan B. Colowick, M.D., M.P.H. DEF 14A, filed 2026-05-18. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 262,266 + equity 0 + all other 0 = 262,266, summed across the director compensation table rows.
- Alumis Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-05-18. CEO total compensation as printed in Alumis Inc's own proxy. As printed: 5,948,289. View filing ↗